The numbers of foxp3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status

Cancer Investigation

Volumn 29, Issue 6, 2011, Pages 419-425

  Gupta, Raavi ^a,c   Babb, James S ^a   Singh, Baljit ^a   Chiriboga, Luis ^a   Liebes, Leonard ^b   Adams, Sylvia ^b   Demaria, Sandra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c University Hospital of Brooklyn   (United States)

Author keywords

Breast cancer; Immunology Immunobiology; Tumor immunology

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENTINEL LYMPH NODE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; SENTINEL LYMPH NODE BIOPSY; T-LYMPHOCYTES, REGULATORY;

EID: 79958201888     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.585193     Document Type: Article

References (44)

1. Krag D., Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998;339:941-946. (Pubitemid 28455095)
2. Khan SA, Eladoumikdachi F. Optimal surgical treatment of breast cancer: implications for local control and survival. J Surg Oncol 2010;101:677-686.
3. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220-227.
4. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-272. (Pubitemid 32575367)
5. Kim R, Emi M, Tanabe K, Arihiro K. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 2006;7:1006-1016. (Pubitemid 44804142)
6. Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 2006;106:1227-1236. (Pubitemid 43363898)
7. KohrtHE,NouriN,Nowels K, Johnson D,Holmes S, Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005;2:e284.
8. Huang RR, Wen DR, Guo J, Giuliano AE, Nguyen M, Offodile R, Stern S, Turner R, Cochran AJ. Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast J 2000;6:225-232. (Pubitemid 30622094)
9. Schüle J, Bergkvist L, Håkansson L, Gustafsson B, Håkansson A. Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients, Breast Cancer Res Treat 2002 74,33-40. (Pubitemid 34734594)
10. Schüle JM, Bergkvist L, Håkansson, L Gustafsson B, Håkansson A CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression J Transl Med 2004 2 45.
11. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-767.
12. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761. (Pubitemid 34921025)
13. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-5380. (Pubitemid 46623168)
14. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Pace L, Valet F, Kissenpfennig A, Sparwasser T, Malissen B, Fetler L, Amigorena S. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010;32:266-278.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336. (Pubitemid 36432314)
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061. (Pubitemid 36222930)
17. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJJ, Wunderlich JR, Merino MJ, Rosenberg SA. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate inmetastaticmelanoma lesions. Blood 2008;112:4953-4960.
18. Kryczek I, Liu R,Wang G,Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, ZouW. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009;69:3995-4000.
19. Yakirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 2007;25:2506-2508. (Pubitemid 47041221)
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949. (Pubitemid 39273735)
21. Petersen RP,Campa MJ, Sperlazza J,Conlon D, Joshi MB,Harpole DHJ, Patz EFJ. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-2872. (Pubitemid 44937041)
22. KobayashiN,Hiraoka N, Yamagami W,OjimaH,Kanai Y,Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-911. (Pubitemid 46340366)
23. Nakamura R, Sakakibara M, Nagashima T, Sangai T, Arai M, Fujimori T, Takano S, Shida T, Nakatani Y,MiyazakiM. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer 2009;45:2123-2131.
24. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 2009;9:231.
25. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,HayesM,Hicks DG, Lester S, Love R, Mangu PB, McShane L,Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, SasanoH, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T,Williams RB,Wittliff JL,Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol LabMed 2010;134:907-922.
26. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia- Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005;23:6107-6116.
27. Matkowskyj KA, Schonfeld D, Benya RV. Quantitative immunohistochemistry by measuring cumulative signal strength using commercially available software photoshop and matlab. J Histochem Cytochem 2000;48:303-312.
28. Reger V, Beito G, Jolly, PC. Factors affecting the incidence of lymph node metastases in small cancers of the breast. Am J Surg 1989;157:501-502. (Pubitemid 19127468)
29. Gruel N, Lucchesi C, Raynal V, Rodrigues MJ, Pierron G, Goudefroye R, Cottu P,Reyal F, Sastre-Garau X, Fourquet A, Delattre O, Vincent-Salomon A. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer 2010;46:2399-2407.
30. Turashvili G, Bouchal J, Baumforth K,WeiW, DziechciarkovaM, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P, Kolar Z. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007;7:55.
31. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang CY, Zheng P, Liu Y. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007;129:1275-1286. (Pubitemid 46970708)
32. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, M̀enard S, Tagliabue E., Balsari A. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009;27:1746-1752.
33. Gobert M,Treilleux I,Bendriss-VermareN Bachelot TGoddard- Leon S,Arfi V, Biota C,Doffin AC,Durand I,Olive D,Perez S,Pasqual N,Faure C,Ray-Coquard I,Puisieux A,Caux C,Blay JY,Méenéetrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome Cancer Res 2009, 69,2000-2009.
34. Clarke SL, Betts GJ, Plant A,Wright KL, El-Shanawany TM, HarropR, Torkington J, Rees BI,WilliamsGT, GallimoreAM, Godkin AJ. CD4+CD25+FOXP3+regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006;1:e129.
35. Demaria S, VolmMD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, SymmansWF. Development of tumor infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001;7:3025-3030. (Pubitemid 32963819)
36. Apetoh L, Ghiringhelli F, Tesniere A, ObeidMOrtiz C,Criollo A,Mignot G,Maiuri MC,Ullrich E Saulnier P,Yang H,Amigorena S,Ryffel B,Barrat FJ, Saftig P,Levi F,Lidereau R,Nogues C,Mira JP,Chompret A,Joulin V,Clavel-Chapelon F,Bourhis J,Andrée F,Delaloge S,Tursz T,Kroemer G,Zitvogel L.Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy NatMed 2007,13 1050-1059 (Pubitemid 47517504)
37. Ghiringhelli F,Apetoh L,Tesniere A,Aymeric L,Ma Y,Ortiz C,Vermaelen K,Panaretakis T,Mignot G,Ullrich E,Perfettini JL,Schlemmer F,Tasdemir E,Uhl M,Géenin P,Civas A,Ryffel B,Kanellopoulos J,Tschopp J,Andrée F,Lidereau R,McLaughlin NM,Haynes NM,Smyth MJ,Kroemer G,Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors Nat Med 2009,15,1170-1178
38. Zitvogel L,Apetoh L,Ghiringhelli F,Andrée F,Tesniere A Kroemer G.The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008 118 1991-2001. (Pubitemid 351872317)
39. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, SinghB, Bauer JA,HochmanT,Goldberg JD,MuggiaF, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 2010;124:723-724.
40. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 2008;26:1024-1031.
41. Denkert C,Loibl S,Noske A,Roller M,M üller BM,Komor M,Budczies J,Darb-Esfahani S,Kronenwett R,Hanusch C,von T örne C,Weichert W,Engels K,Solbach C.,Schrader I,Dietel M,von Minckwitz G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 2010; 28 105-113
42. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E.Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-3633. (Pubitemid 43121851)
43. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009;1174:99-106.
44. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colonystimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-5918.